Cantor Fitzgerald reiterates an Overweight rating on Avita Medical (RCEL) following the company receiving FDA premarket approval for RECELL GO Mini, its miniaturized device designed to treat smaller wounds that aren’t addressed by RECELL GO. Importantly, the firm expects that approval for Mini will allow the company to target smaller wounds within the company’s full thickness skin defect indication. Cantor notes Avita plans to roll out Mini across trauma and burn centers that treat smaller wounds during Q1 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCEL:
- Avita Medical initiated with a Buy at D. Boral Capital
- Closing Bell Movers: International Seaways up 8% on S&P600 inclusion
- Avita Medical discloses FDA premarket approval for ECELL GO mini
- Avita Medical announces FDA 510 clearance for Cohealyx
- Avita Medical enters exclusive distribution agreement with Revolution Surgical